Evolus (NASDAQ:EOLS) Reaches New 12-Month Low – Should You Sell?

Evolus, Inc. (NASDAQ:EOLS) shares reached a new 52-week low on Wednesday . The company traded as low as $10.16 and last traded at $10.21, with a volume of 505260 shares trading hands. The stock had previously closed at $10.74.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Needham & Company LLC restated a “buy” rating and set a $22.00 price target on shares of Evolus in a research note on Friday, September 13th. Cantor Fitzgerald reissued an “overweight” rating on shares of Evolus in a research report on Monday, September 16th. Barclays upped their price target on Evolus from $16.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, September 13th. Finally, HC Wainwright reissued a “buy” rating and issued a $27.00 price objective on shares of Evolus in a report on Thursday, November 7th.

Evolus Stock Performance

The business has a 50 day moving average of $12.38 and a 200-day moving average of $13.72. The company has a market capitalization of $633.20 million, a P/E ratio of -10.99 and a beta of 1.27. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47.

Institutional Investors Weigh In On Evolus

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Caligan Partners LP raised its position in shares of Evolus by 1.2% during the 3rd quarter. Caligan Partners LP now owns 2,193,488 shares of the company’s stock valued at $35,535,000 after buying an additional 25,698 shares in the last quarter. Geode Capital Management LLC increased its stake in Evolus by 0.9% in the third quarter. Geode Capital Management LLC now owns 1,210,621 shares of the company’s stock valued at $19,616,000 after acquiring an additional 11,027 shares during the last quarter. Lord Abbett & CO. LLC raised its position in Evolus by 23.4% during the third quarter. Lord Abbett & CO. LLC now owns 995,449 shares of the company’s stock valued at $16,126,000 after purchasing an additional 188,685 shares in the last quarter. Assenagon Asset Management S.A. lifted its stake in Evolus by 0.9% during the third quarter. Assenagon Asset Management S.A. now owns 955,555 shares of the company’s stock worth $15,480,000 after purchasing an additional 8,452 shares during the last quarter. Finally, Rice Hall James & Associates LLC boosted its holdings in shares of Evolus by 6.3% in the 3rd quarter. Rice Hall James & Associates LLC now owns 904,900 shares of the company’s stock worth $14,659,000 after purchasing an additional 53,605 shares in the last quarter. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.